SSY Group gains approval for Parkinson's drug in China

SSY Group Limited (HKEX: 2005) announced that its Piribedil drug has received approval for registration from China's National Medical Products Administration, authorizing it for bulk drug production. This milestone marks the third such approval for PRC entities and positions Piribedil for wider market preparations. Piribedil is primarily indicated for the treatment of Parkinson's disease and circulatory disturbances. The company stated that this voluntary announcement is intended to keep shareholders and potential investors updated on the latest business developments of the Group. The board of directors, as of February 24, 2025, consists of several executive, non-executive, and independent non-executive directors, including Qu Jiguang and Chow Hing Yeung.